Novogen : receives $4.4m R&D tax rebate

ASX:NRT NASDAQ:NVGN

Novogen Ltd (Company)

ABN 37 063 259 754

27 March 2017

Capital Structure

Ordinary Shares on issue:

483 M

Board of Directors

Chairman

Non-Executive Director

Deputy Chairman

Non-Executive Director

Chief Executive Officer Managing Director

Non-Executive Director

Non-Executive Director

Non-Executive Director

Sydney, 27thMarch 2017 -Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology- focused biotechnology company, is pleased to confirm receipt of $4.4m from the Australian Taxation Office under the R&D Tax Incentive Program for the financial year ending 30 June 2016. These funds will be utilised to support the Company's ongoing clinical programs.

Novogen CEO, Dr James Garner said "the R&D tax rebate is an important, non-dilutive source of funding for Novogen. The $4.4m is in line with our expectations as reported in the Company's half yearly report, and will be allocated primarily to progressing our clinical trials for Cantrixil and GDC-0084."

Novogen's research and development is directed towards developing meaningful new treatments for cancers where there is a high area of unmet need. The Company has a strong pipeline of drug development assets, ranging in stage from pre-clinical assets to later stage programs, Cantrixil and GDC-0084.

[ENDS]

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of four development candidates, diversified across three distinct technologies, with the potential to yield first-in-class and best-in-class agents across a range of oncology indications.

The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. Three further molecules have been developed in-house from two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) to treat ovarian cancer and a range of solid tumours. Cantrixil, the most advanced of these, commenced a first-in-human clinical study in patients with ovarian cancer in late 2016, while Anisina and Trilexium are in preclinical development.

For more information, please visit: www.novogen.com